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Abstract
Background: There are no previous reports of paliperidone palmitate’s (PP) long term tolerability or
pharmacokinetics of the highest dose in patients with schizophrenia. This study evaluates safety and tolerability, as
well as pharmacokinetics, of the highest marketed dose of PP (150 mg eq. [234 mg]) in stable patients with
schizophrenia over a 1-year period.
Methods: In this 1-year prospective study, eligible patients (aged 18-65 years; Positive and Negative Syndrome
Scale’s total score ≤ 70) received an initial deltoid injection of PP 150 mg eq. The second injection one week later
and subsequent once-monthly injections were deltoid or gluteal. All injections were to be PP 150 mg eq. Patients
willing to participate in intensive pharmacokinetic sampling were classified as Treatment A. Patients unwilling to
undergo intensive pharmacokinetic sampling or unable to tolerate the 150 mg eq. dose (consequently receiving
flexible doses of 50, 100 or 150 mg eq.) were classified as Treatment B.
Results: Of the 212 patients (safety analysis set), 73% were men; 45% white; 20% black; 34% Asians; mean (SD) age
41 (10.2) years, and mean (SD) baseline Positive and Negative Syndrome Scale total score 54.9 (9.03). A total of 53%
(n = 113) patients completed the study and 104 received PP 150 mg eq. throughout. Mean (SD) mode dose of PP
was 144.8 (19.58) mg eq. The dosing initiation regimen resulted in rapidly achieved and maintained therapeutic
paliperidone levels over the study (average concentrations during the dosing interval were 34.7, 40.0, and 47.8 ng/
mL after the 2nd, 8th, and 14th injection respectively). Most frequent (≥ 10%) treatment-emergent adverse events
were nasopharyngitis (n = 37), insomnia (n = 32), injection-site pain (n = 32), headache (n = 28), and tachycardia (n
= 27). Akathisia (n = 19) and tremor (n = 11) were the most common extrapyramidal adverse events. 33 patients
had an SAE and 27 discontinued due to treatment-emergent adverse events. No deaths were reported. Mean (SD)
weight change from baseline was 2.5 (5.41) kg at endpoint. Patients’ psychoses remained stable.
Conclusions: Safety results after one-year therapy with the highest available dose of once-monthly paliperidone
palmitate were consistent with results from previous studies, with no new concerns noted. Plasma concentrations
were within the expected range.
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Background
Schizophrenia is a serious and chronic mental disorder
requiring continuous and long-term therapy with anti-
psychotics [1]. Treatment non-adherence to daily oral
antipsychotics and the associated risk of symptom
relapse or recurrence are some of the global challenges
prevalent among patients with schizophrenia [2,3]. As
compared with the oral formulations, the long-acting
injectable (LAI) formulations of antipsychotic drugs
have the advantage of a sustained release profile provid-
ing therapeutic plasma concentration for several weeks
[4], thereby eliminating the need for daily oral medica-
tion [5-7]. Thus, LAIs ensure continuous drug exposure,
mitigating the risk of nonadherence associated with oral
agents, and can provide symptom control with lower
overall plasma concentrations [1,8].
Paliperidone palmitate (PP) is a once-monthly inject-
able atypical antipsychotic recently approved in the Uni-
ted States for the acute and maintenance treatment of
schizophrenia in adults [9]. Treatment with PP does not
require oral supplementation during initiation, as its
pharmacokinetic (PK) profile allows both a rapid
achievement of therapeutic plasma levels of paliperidone
as well as a gradual and continuous release of the drug
over the dosing interval [10]. The approved recom-
mended initiation regimen [9] with deltoid injections of
a high dose of PP (150 milligram equivalent [mg eq.].
on day 1 and 100 mg eq. on day 8) allows rapid attain-
ment of therapeutic concentrations [11,12].
In this phase-1 study, a higher than recommended 2nd
dose in the initiation regimen of PP (150 mg eq. on day
1 and 150 mg eq. on day 8) and the highest recom-
mended maintenance dose were used to evaluate the
long-term (up to 1 year) safety and tolerability of the
highest available dose of PP 150 mg eq. and to evaluate
the PK data at steady state, which is expected to occur
after 6-8 injections of PP 150 mg eq.
Methods
Patients
Consenting men and women aged, 18 to 65 years (inclu-
sive) who were diagnosed with schizophrenia per Diag-
nostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV) at least one year before
screening and with a PANSS total score of ≤ 70 at
screening were enrolled. Other important inclusion cri-
teria included: Body Mass Index (BMI) of ≥ 17.0 kg/m2
at screening, and ability to provide informed consent,
including refusal or consent for optional pharmacoge-
nomic research.
Main exclusion criteria included: primary active DSM-
IV Axis I diagnosis other than schizophrenia, involun-
tary commitment to psychiatric hospitalization, previous
treatment with injectable antipsychotic formulations
other than PP or risperidone-LAI) within 1 injection
interval on day 1, previous PP injection within 10
months or risperidone-LAI injection within 100 days
before day 1, at significant risk of suicidal or violent
behavior, history of neuroleptic malignant syndrome or
tardive dyskinesia (TD), hypersensitivity to risperidone,
paliperidone or their excipients, history of significant or
unstable systemic disease, or history or presence of cir-
cumstances that would increase the risk of torsade de
pointes or sudden death associated with the use of
drugs that prolong QT interval.
Study design
This was a phase 1 open-label, long-term, multiple-dose,
and multicenter study conducted from September 2007
to June 2009 at 30 centers in 10 countries (Belgium,
Croatia, Spain, the Republic of Korea, Malaysia, Poland,
Slovakia, Thailand, Taiwan, and the United States) in
accordance with the ethical principles that have their
origin in the Declaration of Helsinki, and that was con-
sistent with Good Clinical Practices and applicable regu-
latory requirements. The Independent Ethics Committee
or Institutional Review Board at each study site
approved the protocol and all patients provided written
informed consent prior to entering the study.
The study consisted of a screening and washout phase
of up to 21 days (including oral tolerability testing with
paliperidone extended release [ER] 6 mg/day for 4 to 6
consecutive days for patients without documented pre-
vious exposure to risperidone or paliperidone) and a 53-
week open-label treatment phase (approximately 56
weeks in total) (Figure 1). All injections were planned to
be PP 150 mg eq. Patients on PP 150 mg eq. willing to
participate in intensive PK sampling formed the primary
analysis group (Treatment A). Patients who declined to
participate in Treatment A, either due to the intensive
PK sampling or if they could not tolerate the 150 mg
eq. dose of PP, were still allowed to participate in Treat-
ment B with less frequent PK sampling. All patients
began the study entering into Treatment A, and were
allowed to switch to Treatment B (dose range 50-150
mg eq.) after the first injection, at the discretion of the
investigator.
During the study, previous oral or injectable antipsy-
chotics (except risperidone, paliperidone ER or cloza-
pine) were to be stopped 3 days before the start of the
study. Clozapine was not allowed within 6 weeks before
day 1 and risperidone or paliperidone ER were discon-
tinued at least 5 days before the first injection. Antipar-
kinsonism drugs were allowed only if necessary, and
were otherwise tapered to discontinuation 1 day before
the screening or washout phase.
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All patients received an initial dose of PP 150 mg eq.
in the deltoid muscle (day 1) and the subsequent second
injection (day 8) in the deltoid (Treatment A), or in
either the deltoid or gluteal muscle (Treatment B). In
both groups, the 12 subsequent injections were adminis-
tered every 4 weeks in either the deltoid or gluteal mus-
cle alternating between sides (left/right) (Figure 1).
Psychiatric and safety assessments were performed peri-
odically throughout the study.
Study medication
Paliperidone palmitate doses can be expressed both in
terms of mg eq. of the pharmacologically active fraction,
paliperidone, and in mg of PP. Thus, the doses
expressed as PP 50, 100, or 150 mg eq. equate to PP 78,
156, and 234 mg, respectively. Paliperidone palmitate
was supplied as injectable suspensions (50,100, 150 mg
eq.) in prefilled syringes with 22 and 23 gauge needles.
Needle gauge was based on intramuscular injection site
(deltoid or gluteal) and patient body weight.
Study assessments
Pharmacokinetic assessments
Throughout the study, 4 mL of venous blood samples
were taken at all visits for Treatment A and at selected
visits for Treatment B (Figure 1) to determine plasma
paliperidone concentration.
Samples were collected before study drug administra-
tion (if scheduled). On days when 12-lead ECGs were
recorded, the PK blood samples were collected as soon
as possible after the 12-lead ECG. Plasma concentrations
Men and women with
schizophrenia aged18-
65 yrs
Total PANSS <=70 
Treatment A
(N=186)
Treatment B
(N=26)
Screening
Day 36 to Day 344 
Study medication 
dosing
PK Sampling
 234 mg 
(deltoid or gluteal)
FIXED DOSE
78 – 234 mg 
FLEXIBLE DOSE
Day 1: Predose 24, 72 and 120 
hours
Predose or same time as prior
injection: Days 8, 11, 15,18, 20,
22, 29, 36, 41, 64, 92, 99, 120,
148, 155, 176, 179, 183, 186,
188, 190, 197, 204, 232, 260,
288, 316, 344, 347, 351, 354,
356, 358, 365, 372
Predose: Days 8, 64, 
120, 176, 232, 288,
344
Same time as prior
injection: Day 372
Unable to
tolerate 234 
mg  or
unwilling to 
participate in
intensive PK
sampling
Study
Completion
(n=100)
Day 1 injection
234 mg ( Deltoid)
Discontinuations: (n=86)
Patient choice (n =27)
Adverse event (n=23)
Lack of efficacy (n=15)
Lost to follow-up (n= 9)
Other (n=12) Study
Completion
(n=13)
Discontinuations: (n=13)
Patient choice (n=2)
Adverse event (n=5)
Lack of efficacy (n=2)
Lost to follow-up (n= 3)
Other (n=1)
234 mg ( Deltoid)
Day 8 injection
Figure 1 Study Design. PK - pharmacokinetic.
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of paliperidone were determined in 2 laboratories (Bioa-
nalytical Department, Janssen Research & Development,
LLC, Beerse, Belgium and Frontage Laboratories Co.,
Ltd., Shanghai, China). A validated liquid chromatogra-
phy coupled to tandem mass spectrometry (LC-MS/MS)
methods with a target limit of quantification (LOQ) of
0.1 ng/mL was used. Before sample analysis, a cross-
validation of study samples previously analyzed by Fron-
tage Laboratories was performed. Pharmacokinetic ana-
lysis and descriptive statistics were performed using
PKAA version 2.1b (developed by Intrasphere Technolo-
gies, London, U.K); and using WinNonLin 5.2.1 (Phar-
sight, Mountain View, California, U.S.).
The plasma PK parameters estimated for each patient
in Treatment A who had intensive PK sampling
included: i) plasma concentration measured immediately
before the i.m. injections (Cpredose); ii) observed maxi-
mum plasma concentration (Cmax) and minimum
plasma concentration (Cmin), time to reach the maxi-
mum plasma concentration (tmax), and area under the
plasma concentration-time curve within the interval of
28 days (AUCτ) after the 2
nd, 8th, and 14th injections; iii)
average plasma concentration (Cavg), calculated as the
AUCτ after the 2
nd, 8th and 14th injections divided by
the dosing interval; iv) fluctuation Index (FI): percentage
fluctuation (variation between peak and trough at
steady-state), calculated as 100*[(Cmax-Cmin)/Cavg].
Population-PK model
The historical model [11] was examined for its predic-
tive ability and its performance was evaluated on the
current data set that was not used in model building
exercise. Population predictions for all concentrations in
the evaluation data set were obtained using the dosing
and necessary covariate information. Prediction errors
were computed that provide a measure of bias and pre-
cision by assessing the differences between the measured
and population mean predicted concentrations. The pre-
diction error percents (PE%) were computed for each
concentration value using the equation: PE%ij = (DVij-
PREDij)/PREDij* 100, where, PE%ij is the percent predic-
tion error between the ith value of the dependent vari-
able in the jth subject; and the population prediction of
the ith observation in the jth subject; DVij is the value of
the ith observation (i.e. the dependent variable) in the jth
subject; and PREDij is the population prediction of the
ith observation in the jth subject.
The absolute prediction error percents (|PE|%) was
computed as the absolute value of the PE%. Summary
statistics of PE% and |PE|% were calculated to assess
bias and precision of the model-predicted concentra-
tions relative to the observed concentrations. The distri-
bution of PE% was evaluated as a measure of bias and
the distribution of |PE|% was utilized as a measure of
precision in the predicted values. The model was
considered acceptable, both accurate and precise, (i.e.,
externally validated) if the median PE% and the median
|PE|% were ≤ |15|% and 30%, respectively [11,13-15].
In addition, the model was subjected to model verifi-
cation using a visual predictive check [11]. Finally, the
population PK model was also used to evaluate the
effect of ethnicity and BMI on the PK of PP.
Safety assessments
Safety assessments included evaluation of treatment-
emergent adverse events (TEAEs), extrapyramidal symp-
toms (EPS) rating scores based upon the Barnes Akathi-
sia Rating Scale (BARS) [16], Simpson-Angus Rating
Scale [17] (SAS), and Abnormal Involuntary Movement
Scale (AIMS) [18], changes in weight, electrocardio-
grams, vital signs, clinical laboratory data, and subjective
assessment of injection-site pain.
Psychiatric assessments
Psychiatric evaluations included PANSS [19], PSP (Per-
sonal and Social Performance scale) [20], and CGI-S
(Clinical Global Impression-Severity scale) [18], which
were also periodically evaluated by qualified raters to
monitor patient symptoms and to adjust concomitant
psychiatric medications if required.
Statistical methods
Sample size determination
Using an estimated intrapatient coefficient of variation
of 40% for AUCτ and Cmax of paliperidone after PP
injection, and a 5% significance level, a sample size of
40 patients from Treatment A was considered sufficient
for the point estimate of the relative bioavailability after
the 8th i.m. injection of PP 150 mg eq. (the highest
available dose) compared to the 2nd i.m. injection of PP
150 mg eq. to fall within 86.0% and 116.3% of the true
value, with 90% confidence.
A minimum of 100 patients exposed for 1 year was
considered to be an adequate group size and time per-
iod to assess safety and tolerability. Assuming a discon-
tinuation rate of 50%, it was estimated that a total of
200 patients (from either Treatment A or Treatment B)
would need to be enrolled so that at least 100 patients
would complete the study.
Pharmacokinetic analysis
To assess the attainment of apparent steady-state after a
loading dose and to estimate the relative bioavailability
of paliperidone after the 8th injection compared to the
2nd injection, different PK analyses and explorations
were conducted, requiring different exclusion strategies.
The PK data were analyzed using a mixed-effect analysis
of variance model that included the 2nd, 8th or 14th
injections as a fixed effect and patient as a random
effect.
Using the estimated least-squares means and intrasub-
ject variance, the point estimate and 90% confidence
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intervals for the difference in means on a log scale
between the 14th or 8th and 2nd i.m. injections were con-
structed. The limits of the confidence intervals were
retransformed using antilogarithms to obtain 90% confi-
dence intervals for the ratios of the mean AUCτ and
Cmax after the 14
th or 8th i.m. injections of PP 150 mg
eq. versus the 2nd i.m. injection of PP 150 mg eq. As
per study design, no formal statistical comparison of PK
results of patients in Treatment B was performed.
Safety analysis
All patients who received at least 1 dose of the study
drug were included in the safety analyses. Only descrip-
tive statistics were performed.
Psychiatric symptom assessment analysis
All patients who received at least 1 dose of the study
drug and who had at least 1 postbaseline psychiatric
evaluation were included in the statistical analyses of
the psychiatric evaluations. The PANSS, CGI-S, and PSP
scores were summarized descriptively.
Exploratory analysis
Exploratory analysis of the safety data was performed to
compare the safety profile of PP in patients who com-
pleted the trial while receiving 150 mg eq. throughout
and those who did not complete the study at 150 mg
eq. dose of PP (discontinued the dose of 150 mg eq. of
PP or received flexible dose [50-150 mg eq.] at any
time).
Results
Patient disposition and population
Of the 212 enrolled patients, 113 (53%) completed the
study (Figure. 1). Overall, most of the patients were
between 26 to 50 years, most were men and were white.
The mean (SD) age was 40.7 (10.17) years (range: 19 to
65 years) (Table 1).
All patients in the safety analysis set (N = 212) were
initially assigned to Treatment A (to receive fixed doses
of 150 mg eq. PP throughout and participate in inten-
sive PK sampling). Out of these, 12% of patients (n =
26) switched to Treatment B, which allowed them to
either receive continued treatment with PP 150 mg eq.
or to choose a flexible dose option (50-150 mg eq.). All
patients in Treatment B had less frequent PK sampling
than those in Treatment A. Out of the 113 completers,
104 (Treatment A: n = 100; Treatment B: n = 4)
received the 150 mg eq. dose regimen for the entire
study. The major reasons for withdrawal were patient
choice (14%) and adverse events (13%). Nearly 50% of
all patients were exposed to PP for at least 344 days.
Total mean duration of exposure was 250 days (Treat-
ment A: 248 days, Treatment B: 264 days). The overall
mean (SD) mode dose (mean of the most frequently
used dose) of PP was 144.8 (19.58) mg eq. (Treatment
A: 150 mg eq.; Treatment B: 109.6 mg eq.).
In this study, patients in Treatment A formed the pri-
mary analysis group, and all interpretations are presented
for this group. Interpretation of safety results for Treat-
ment B is limited since only a few patients in this group (n
= 7 out of 26; with 4 completing) continued to receive PP
150 mg eq. dose, and the reason for dose adjustments in
this group were not systematically documented. Overall,
16 patients had dose adjustments due to a TEAE.
Table 1 Demographic and baseline characteristics (safety
analysis set)
Treatment A Treatment B
PP 150 mg
eq.
PP 50-150 mg
eq.
Total
(N = 186) (N = 26) (N = 212)
Age (years)
Mean (SD) 41.4 (10.24) 35.7 (8.17) 40.7
(10.17)
Sex, n (%)
Men 138 (74) 16 (62) 154 (73)
Women 48 (26) 10 (38) 58 (27)
Race, n (%)
White 88 (47) 8 (31) 96 (45)
Black 36 (19) 6 (23) 42 (20)
Asian 60 (32) 12 (46) 72 (34)
Othera 2 (1) 0 2 (< 1)
Ethnicity, n (%)
Not Hispanic or Latino 184 (99) 24 (92) 208 (98)
Hispanic or Latino 2 (1) 2 (8) 4 (2)
Weight (kg)
Mean (SD) 78.1 (18.55) 73.5 (16.45) 77.5
(18.33)
Height (cm)
Mean (SD) 170.6 (10.24) 171.0 (9.97) 170.6
(10.18)
Baseline body mass index (kg/m2)
Category, n (%)
Normal < 25 70 (38) 14 (54) 84 (40)
Overweight 25- < 30 66 (35) 7 (27) 73 (34)
Obese ≥ 30 50 (27) 5 (19) 55 (26)
Mean (SD) 26.71 (5.55) 24.91 (4.16) 26.49
(5.42)
Psychiatric Evaluationsb
PANSS total scores, Mean
(SD)
55.5 (8.87) 51.5 (9.86) 55.0 (9.08)
PSP, Mean (SD) 67.3 (10.41) 68.0 (10.01) 67.4
(10.33)
CGI-S, Median (Range) 3.0 (2;6) 3.0 (2;5) 3.0 (2;6)
a includes native Hawaiian or other Pacific islander; b For PANSS and PSP: n =
178 (Treatment A), n = 26 (Treatment B), and n = 204 (Total); For CGI-S: n =
182 (Treatment A), n = 26 (Treatment B), and n = 208 (Total); PANSS- Positive
and Negative Syndrome scale; PSP- Personal and Social Performance Scale;
CGI-S- Clinical Global Impression Severity Score; PP- Paliperidone palmitate,
BMI- Body Mass Index
Coppola et al. BMC Psychiatry 2012, 12:26
http://www.biomedcentral.com/1471-244X/12/26
Page 5 of 14
The effect of repeated deltoid administration could be
assessed in 46 patients (Treatment A: n = 44; Treatment
B: n = 2) who received 14 consecutive deltoid injections
of PP. Frequently used concomitant benzodiazepines
during the study included lorazepam (38%), diazepam
(16%) and clonazepam (10%). Zolpidem (29%) was the
most frequently used non-benzodiazepine drug.
Pharmacokinetic results
Paliperidone exposure approached the exposure at
steady state from the second injection onwards, with the
steady-state levels reached after about 8 to 9 months
(Figure 2). The median average plasma concentration
(Cavg) of paliperidone continued to increase over the
injection period (Table 2). The median Cmax of paliperi-
done was comparable after the 2nd and 8th injections
and slightly higher after the 14th injection of PP (Table
2). The median fluctuation index gradually decreased
over the injection period. The AUCτ was slightly
increased after the 8th injection compared with the 2nd
injection. Mean exposure to PP increased and maximum
plasma concentrations were higher after the 8th and 14th
injections compared with the 2nd injection (Table 3).
Overall, the results indicated that within one week after
the first dose, the majority of patients had plasma con-
centrations above 7.5 ng/mL (Figure 3), the minimum
required plasma paliperidone concentration associated
with a central D2-receptor occupancy of approximately
60% (Karlsson et al., 2006) that is generally considered
the threshold for antipsychotic efficacy. A median
plasma paliperidone concentration of 7.5 ng/mL was
reached between the 2nd and 3rd PK visits (day 2 and
day 4).
The overlay plots comparing results from the popula-
tion PK simulation to the actual observed plasma
concentrations showed considerable similarity and the
majority of the observations were within the 90% predic-
tion interval, confirming agreement between anticipated
temporal PK profile and observed PK data (Figure 2).
Prediction errors were well within cut-off values and
statistical distributions supported the suitability of the
model (Table 4). Although the model was developed on
PK data obtained from 25 weeks treatment after 7 injec-
tions of PP [11], the model also adequately predicted
the PK of paliperidone for 53 weeks treatment after 14
injections (Figure 3).
Using the historical population PK model, the time to
reach 97% of the maximal median concentration
achieved after one year of dosing was calculated. Attain-
ment of 97% steady-state is equivalent to the frequently
used criterion of five times the effective half-life. The
model predicted that 97% of steady state would be
achieved after 38 weeks for multiple deltoid injections of
100-150 mg eq. PP and 42 weeks for multiple gluteal
injections of 100-150 mg eq. PP. The observed median
plasma concentration profile shows that by week 41,
97% of the maximal median concentration was achieved,
indicating that the expectation from the population-PK
model has been met.
The observed median plasma concentration-time pro-
files of paliperidone from Asians and White patients
showed that Asians had approximately 4% higher plasma
exposure to paliperidone compared with White patients
(see Additional file 1), which can be explained by the
lower BMI in the Asian population (see Additional file
2). Furthermore, the population PK analysis showed that
race does not have an independent effect on PK once
the difference in BMI across ethnicities is accounted
(see Additional file 3).
Safety results
Treatment-emergent adverse event
About 184 patients (87%; safety analysis set: n = 212)
experienced at least 1 TEAE during the study. The
majority of these TEAEs were mild to moderate in
severity. The most frequent TEAEs (in ≥ 10% of all
patients) were nasopharyngitis (17.5%), insomnia (15%),
injection-site pain (15%), tachycardia (13%), and head-
ache (13%) (Figure 4). There were no deaths reported
during the study. Overall, 33 patients (15.6%) had ser-
ious TEAEs; among which worsening of symptoms of
schizophrenia (5%) and psychotic disorder (3%) were
most commonly reported. In all, 27 patients discontin-
ued the study due to a TEAE (Treatment A: n = 22;
Treatment B: n = 5), mostly due to psychotic disorders
(7.5%), and 11 patients discontinued due to a serious
TEAE (Treatment A: n = 10; Treatment B: n = 1). Of
the 19 patients who had dose adjustments in Treatment
B, dose adjustments were mostly due to a TEAE (in 16
Figure 2 Median plasma concentration-time profiles of
paliperidone (data from 212 patients). Time-concentration
profiles were based on data from 212 patients.
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of 19 patients). Only dystonia, orthostatic hypotension,
asthenia and sluggishness (n = 2 each) were experienced
by more than one patient.
There was no clinically meaningful difference in the
incidence of serious TEAEs between patients who exclu-
sively received deltoid injections (12.9%) and those who
did not receive injections exclusively in the deltoid
(15.6%; safety analysis set). No patient discontinued
from the study due to an adverse event related to the
injection site (e.g. pain).
Other safety events of clinical interest
The majority of patients continued in Treatment A
(88%). The numbers of patients who received PP 150
mg eq. dose throughout the study in Treatment B (n =
7) were not sufficient to conduct a valid comparison
with Treatment A (n = 186).
Overall body weight increases of ≥ 7% (from baseline
to endpoint) occurred in 27% (n = 55) of patients
(Treatment A: n = 55; Treatment B: n = 10). At
endpoint, mean body weight increased by 3.9% and
mean (SD) weight increased 2.5 (5.41) kg from baseline.
All patients with an adverse event of diabetes mellitus
(< 2%; n = 4) were either obese or overweight and had
either diabetic or prediabetic range fasting plasma glu-
cose at screening or baseline. One of the 4 patients had
a history of impaired glucose tolerance, and 1 had a
baseline elevation of hemoglobin A1C. There were no
other treatment-emergent glucose-related adverse
events. There were no clinically relevant mean changes
from baseline to any timepoint in lipids.
EPS-related TEAEs occurred in 50 (of 212, safety ana-
lysis set) patients (24%) during the study (Treatment A
[20%; n = 38/186] Treatment B [46%; n = 12/26]). The
majority of these were non-serious, mild to moderate in
intensity. Data on preexisting EPS-related events of the
patients enrolled were not collected. After treatment
initiation, the proportion of EPS-related TEAEs was <
5% (n = 7; 3%) from day 1 to day 8; increased to 13% (n
Table 3 Plasma pharmacokinetic parameters of paliperidone following injections of paliperidone palmitate (150 mg
eq.) (pharmacokinetic analysis set)
Geometric Ratio Confidence Interval
PK parameter Injection N LSM (Test/Reference)a (90%)
AUCτ, ng.h/mL 2nd injection 96 21924.25
8th injection 96 26638.65 121.50 (114.42;129.03)
14th injection 96 31522.41 143.78 (135.39;152.68)
Cmax, ng/mL 2nd injection 99 46.74
8th injection 99 49.42 105.75 (98.82;113.16)
14th injection 99 57.74 123.55 (115.46;132.21)
Note: Data analyzed on log-scale but transformed back to the original scale
LSM = Least-Squares Means
a Test refers to 8th/14th injection and Reference refers to 2nd injection
Table 2 Median pharmacokinetic parameters after intramuscular injections of paliperidone palmitate (150 mg eq.)
2nd injection 8th injection 14th injection
PK parameter N Median
(min-max)
N Median
(min-max)
N Median
(min-max)
Cpredose, ng/mL 200 21.3
(0.46-81.2)
119 28.4
(6.03-92.6)
105 39.9
(9.17-134)
Cmin, ng/mL 189 17.0
(0.46-46.7)
114 27.0
(6.03-92.6)
105 35.1
(9.17-120)
Cmax, ng/mL 189 50.5
(11.5-232)
114 50.5
(10.7-172)
105 56.5
(17.6-172)
tmax, days
a 189 7.96
(0.00-28.02)
114 8.48
(0.00-30.95)
105 7.00
(0.00-30.00)
AUCtau, h*ng/mL 183 23325
(3652-86457)
111 26831
(6335-87393)
105 31970
(9244-96840)
Cavg, ng/mL 183 34.7
(5.44-129)
114 40.0
(9.42-130)
105 47.8
(13.8-144)
FI, % 183 92.7
(39.8-215)
114 55.0
(15.6-179)
105 41.2
(5.83-111)
atmax was calculated in hours and recalculated to days here. FI = fluctuation index
Coppola et al. BMC Psychiatry 2012, 12:26
http://www.biomedcentral.com/1471-244X/12/26
Page 7 of 14
= 28) during subsequent month (from day 9 to day 36),
and subsequently remained < 5% per month interval
thereafter. Overall, 30% of the enrolled patients (n = 64)
had received prior anti-EPS medication and 10% of
these patients (n = 21) continued to receive anti-EPS
medications in the study. A total of 22% of patients (n =
46) received anti-EPS medication during the study. Five
patients required PP dose adjustments due to EPS-
related TEAEs. Overall, 4 patients experienced serious
EPS-related TEAEs and 4 patients (all from Treatment
A) discontinued due to EPS-related TEAEs. EPS-related
TEAEs occurring in at least 5% of total patients were
akathisia (n = 19) and tremor (n = 11).
Based on mean changes in EPS rating scales, patients
were slightly more symptomatic for akathisia, dyskinesia,
and parkinsonism at endpoint versus baseline. At end-
point, overall rates were: 1%, akathisia (n = 3; based on
BARS clinical rating); 2%, dyskinesia (n = 5; based on
AIMS score); and 16%, parkinsonism (n = 34/212; based
on SAS global score) (Treatment A [16%; n = 29/186];
Treatment B [19%; n = 5/26]).
Potentially prolactin-related TEAEs occurred in 41
patients (19%; Treatment A [16%; n = 30/186]; Treat-
ment B [42%; n = 11/26]) and led to discontinuation in
3 patients (Treatment A: n = 1; Treatment B: n = 2).
The majority of these events were incidental laboratory
abnormalities without reported signs and symptoms of
clinically relevant hyperprolactinemia. Incidences of
potentially prolactin-related TEAEs were higher in
women (32.8%, n = 19/58) than in men (14.3%, n = 22/
154). Among the clinical signs and symptoms, only
libido decreased (n = 4), erectile dysfunction (n = 2) and
amenorrhoea (n = 2) were reported as TEAEs in more
than 1 patient. Seventy-eight percent of the patients had
treatment-emergent abnormal prolactin levels (Treat-
ment A: n = 144 [77%]; Treatment B: n = 21 [81%]).
Mean (SD) prolactin levels increased from baseline to
endpoint in both women (Treatment A: 78.3 [48.8] ng/
mL; Treatment B: 92.3 [45.8] ng/mL) and men (Treat-
ment A: 28.6 [22.00] ng/mL; Treatment B: 29.6 [17.4]
ng/mL). Prolactin concentrations were observed to be
the highest at the time of Cmax and then decreased to
the Day 372 timepoint in women (Figure 5). In men, a
steady elevation was present until study endpoint.
Mild TD (described as “increased lip movements”) was
reported as a TEAE in one patient, which resolved on
Table 4 Tabular results for the external validation: distribution for PE% and |PE|% to assess bias and precision
respectivelya
Nb Observed
Median
Median cut-off to pass
validation
Observed 25th
percentile
Observed 75th
percentile
Prediction error percents (PE%) 5382 0.72 ± 15 -9.37 10.47
Absolute prediction error percents (|PE|
%)
5382 9.96 30 4.55 17.65
a The prediction error percents (PE%) were computed for each concentration value using the equation below and the absolute prediction error percents (|PE|%)
was computed as the absolute value of the PE%. PE%ij = (DVij- PREDij)/PREDij* 100, where, PE%ij is the percent prediction error between the i
th value of the
dependent variable in the jth subject; and the population prediction of the ith observation in the jth subject; DVij is the value of the i
th observation (i.e. the
dependent variable) in the jth subject; and PREDij is the population prediction of the i
th observation in the jth subject.
bN refers to the number of pharmacokinetic samples used in the calculation of the PE% and |PE|% statistics. The 5382 pharmacokinetic samples were derived
from 211 patients.
Figure 4 Treatment-emergent adverse events experienced by
at least 5% of patients (Safety Analysis Set).
Figure 3 Visual predictive check comparing results from the
population PK simulation to the actual observed plasma
concentrations. PK-pharmacokinetic. Data included is of 192
patients who received 150 mg eq. paliperidone palmitate till the
time of their discontinuation.
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its own with continued PP treatment. The event was
considered as possibly related to study drug. Treatment-
emergent adverse events of orthostatic hypotension (n =
18) were mild in severity and did not lead to disconti-
nuation. Treatment-emergent tachycardia (n = 27) and
syncope (n = 2) led to discontinuation of 1 patient each
in the study. There was no incidence of QT interval cor-
rected (QTc) prolongation > 500 ms in either treatment
group, or no patients experienced an increase of > 60
ms from average predose linear-derived QTc (QTc LD)
interval. There were no clinically relevant mean changes
in laboratory values. Changes in vital sign parameters
occurred with 61% of patients experiencing increases in
standing pulse rates and 32% experiencing increases in
supine pulse rates above clinically important limits
(increase ≥ 15 beats/minute and value ≥ 100 beats/min-
ute). Orthostatic changes in blood pressure (defined as a
decrease in systolic blood pressure of ≥ 20 mm Hg, or a
decrease in diastolic blood pressure of ≥ 10 mm Hg
after standing for at least 2 minutes with an increase in
pulse rate of ≥ 15 beats per minute) occurred in 22% of
patients. Overall, injection-site tolerability was good.
Psychiatric symptom evaluations
Of the 212 patients in the safety analysis set, 209 had at
least one postbaseline psychiatric evaluation. Patients
enrolled in the study were required to be clinically
stable with a PANSS score ≤ 70. Mean total PANSS
scores remained stable over time (Figure 6). Overall,
30% of all patients enrolled had 30% or greater improve-
ment in the PANSS scores from baseline to endpoint. A
total of 204 patients were reported with worsening in
PANSS scores from baseline to endpoint, of which 25%
of patients had a worsening of 30% or greater. There
were no overall clinically meaningful mean changes in
either PSP or CGI-S scores in the group over the course
of the study, and patients in both treatment groups
remained stable.
Exploratory analysis outcome
The exploratory analysis showed that the demographic
and baseline characteristics were similar among
patients who completed the trial while receiving 150
mg eq. throughout and those who did not complete
the study at 150 mg eq. dose of PP. Out of 104
patients who completed the study at 150 mg eq. dose
of PP throughout, 87 patients (83.7%) experienced at
least 1 TEAE; of the 108 patients who did not com-
plete the study at 150 mg eq. dose of PP throughout,
97 (89.8%) reported at least 1 TEAE (Table 5). The
TEAEs reported with highest incidences were naso-
pharyngitis (19.2%, n = 20) and tachycardia (19.2%, n
= 20) for those who completed the study at the dose
of 150 mg eq.; and insomnia (18.5%, n = 20) for those
who did not complete the study at 150 mg eq. dose of
PP (Table 5). Five patients (4.8%) of those who com-
pleted the study at 150 mg eq. dose of PP; and 28
(25.9%) of those who did not complete the study at
150 mg eq. dose of PP were reported with serious
TEAEs (Table 6). Schizophrenia (worsening of symp-
toms) was the serious TEAE with the highest incidence
in those who completed the study at 150 mg eq. dose
of PP throughout the study duration (n = 3, 2.9%) as
well as in those who did not complete the study at 150
mg eq. dose of PP (n = 8, 7.4%) (Table 6).
EPS-related TEAEs were reported in 16.3% (n = 17) of
patients who completed the study at the dose of 150 mg
eq. of PP, while an incidence rate of 30.6% (n = 33) was
reported in patients who did not complete the study at
150 mg eq. dose of PP. Parkinsonism was the most fre-
quently reported TEAE (n = 7, 6.7%) in patients who
completed the study at 150 mg eq. dose of PP; and
hyperkinesia was the most frequently reported TEAE (n
Figure 5 Mean changes in prolactin overtime. Figure 6 Mean PANSS total score (+/- SD) over time from
baseline-LOCF (Psychiatric Evaluation Analysis Set). PANSS-
positive and negative syndrome scale; LOCF- Last observation
carried forward; Pali - paliperidone palmitate; BL- baseline; D - day.
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= 17, 15.7%) in patients who did not complete the study
at 150 mg eq. dose of PP.
Prolactin-related TEAEs were reported in 13.5% (n =
14) of patients who completed the study at 150 mg eq.
of PP; and 25.0% (n = 27) of those who did not com-
plete the study at 150 mg eq. dose of PP. Increased
blood prolactin was the most frequently reported TEAE
in both those who completed the study at the dose of
150 mg eq. (n = 12, 11.1%) and those who did not com-
plete the study at 150 mg eq. dose of PP (n = 7, 6.7%).
The mean change [SD] in the body weight and BMI
from the open-label baseline to endpoint was high in
patients who completed the study at the dose of 150 mg
eq. (weight: 4.2 [5.22] kg; BMI: 1.5 [1.74] kg/m2) com-
pared with those who did not complete the study at 150
mg eq. dose of PP (weight: 0.6 [5.02] kg; BMI: 0.3 [1.79]
kg/m2).
Discussion
This is the first study to examine the long-term pharma-
cokinetics and tolerability of the highest available dose
of PP (150 mg eq.) as fixed dose injections in patients
with schizophrenia. Shorter-term fixed-dose studies have
shown that PP at doses of 25, 50, 75, 100, or 150 mg eq.
was efficacious and tolerable in the treatment of schizo-
phrenia [10,21-24]. Especially as some dose-related
effects were observed in these previous studies, it was
important to determine if long-term treatment with the
maximum available dose was safe and tolerable. In this
1-year phase-1 study of PP in stable patients with schi-
zophrenia, PP was administered either as fixed doses of
the highest available 150 mg eq. dose or as flexible
doses up to 150 mg eq.). Despite the option for down
titration in the flexible-dose group, the majority of
patients remained in the fixed dose group, and of the 26
patients opting for flexible dosing, 7 continued on 150
mg eq. dosing. That more than half of the patients com-
pleted the trial, and that the majority of those continued
on 150 mg eq for the duration of the study attests to
the tolerability of the highest available dose during long-
term therapy. The results indicate that the safety and
tolerability profile of long-term maintenance dosing
Table 5 Treatment-emergent adverse events in ≥ 5% of patients based on exploratory analysis of the safety data
Patients who completed the study on 150 mg eq.
throughout
Patients who did not complete the study on 150 mg
eq. throughout
Group A
(N = 100)
Group B
(N = 4)
Total
(N = 104)
Group C
(N = 86)
Group D
(N = 22)
Total
(N = 108)
Total no. patients with TEAEs 83 (83.0) 4 (100) 87 (83.7) 76 (88.4) 21 (95.5) 97 (89.8)
Nasopharyngitis 19 (19.0) 1 (25.0) 20 (19.2) 14 (16.3) 3 (13.6) 17 (15.7)
Insomnia 11 (11.0) 1 (25.0) 12 (11.5) 16 (18.6) 4 (18.2) 20 (18.5)
Weight increased 10 (10.0) 1 (25.0) 11 (10.6) 4 (4.7) 4 (18.2) 8 (7.4)
Upper respiratory tract infection 6 (6.0) 1 (25.0) 7 (6.7) 3 (3.5) 2 (9.1) 5 (4.6)
Injection site pain 15 (15.0) 0 15 (14.4) 10 (11.6) 7 (31.8) 17 (15.7)
Headache 13 (13.0) 0 13 (12.5) 11 (12.8) 4 (18.2) 15 (13.9)
Blood prolactin increased 7 (7.0) 0 7 (6.7) 8 (9.3) 4 (18.2) 12 (11.1)
Tachycardia 20 (20.0) 0 20 (19.2) 4 (4.7) 3 (13.6) 7 (6.5)
Orthostatic hypotension 9 (9.0) 0 9 (8.7) 6 (7.0) 3 (13.6) 9 (8.3)
Anxiety 7 (7.0) 0 7 (6.7) 4 (4.7) 4 (18.2) 8 (7.4)
Diarrhoea 6 (6.0) 0 6 (5.8) 6 (7.0) 1 (4.5) 7 (6.5)
Hypertension 8 (8.0) 0 8 (7.7) 1 (1.2) 2 (9.1) 3 (2.8)
Tremor 6 (6.0) 0 6 (5.8) 0 0 0
Pyrexia 5 (5.0) 1 (25.0) 6 (5.8) 0 0 0
Toothache 6 (6.0) 0 6 (5.8) 0 0 0
Akathisia 0 0 0 9 (10.5) 6 (27.3) 15 (13.9)
Psychotic disorder 0 0 0 8 (9.3) 1 (4.5) 9 (8.3)
Schizophrenia 0 0 0 8 (9.3) 1 (4.5) 9 (8.3)
Hyperprolactinaemia 0 0 0 5 (5.8) 3 (13.6) 8 (7.4)
Agitation 0 0 0 5 (5.8) 2 (9.1) 7 (6.5)
Note: Group A consists of all patients who completed the study on 150 mg eq. and stayed on intensive PK sampling throughout; and Group B consists of all
patients who completed the study on 150 mg eq. but were not on intensive PK sampling. Group C consists of patients who withdrew early while on 150 mg eq
and intensive PK sampling. Group D consists of patients who completed the trial while on flexible dose and switched to non-intensive PK sampling (N = 9);
patients who withdrew from the trial while on 150 mg eq. and switched to non-intensive sampling (N = 3); and patients who withdrew from the trial while on
flexible dose and switched to non-intensive sampling (N = 10)
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with PP 150 mg eq. is consistent with that shown in
previous short-term studies that included this dose
[22,23] as well as with studies across the dose range
[10,21,24,25] and no new safety signals emerged. The
overall incidence of TEAEs, and the incidences of ser-
ious TEAEs, EPS-related and prolactin-related TEAEs
were also high in patients who did not complete the
study at 150 mg eq. compared with those who com-
pleted the study at the dose of 150 mg eq. of PP.
The recommended monthly maintenance dose of PP
is 75 mg eq. (117 mg) [9], although some patients may
benefit from higher or lower doses.
Generally, the incidence of discontinuations in this
long-term study (47%) is consistent with rates observed
in previous short duration PP studies [23-25] and also
with rates reported in other drug studies in schizophre-
nia [26,27]. In the current study, patients were exposed
to PP 150 mg eq. for a mean duration of 250 days, and
approximately half the patients completed the study.
Attainment of optimal therapeutic plasma concentra-
tion is important while starting treatment with a LAI
[5]. In this study, a median plasma paliperidone concen-
tration of above 7.5 ng/mL, which is associated with a
central D2-receptor occupancy of approximately 60%
Table 6 Treatment-emergent serious adverse events based on exploratory analysis of the safety data
Patients who completed the study on 150 mg
eq. throughout
Patients who did not complete the study on 150
mg eq. throughout
Group A
(N = 100)
Group B
(N = 4)
Total
(N = 104)
Group C
(N = 86)
Group D
(N = 22)
Total
(N = 108)
Total no. patients with serious TEAEs 5 (5.0) 0 5 (4.8) 24 (27.9) 4 (18.2) 28 (25.9)
Schizophrenia 3 (3.0) 0 3 (2.9) 7 (8.1) 1 (4.5) 8 (7.4)
Psychotic disorder 1 (1.0) 0 1 (1.0) 5 (5.8) 0 5 (4.6)
Anxiety 1 (1.0) 0 1 (1.0) 1 (1.2) 0 1 (0.9)
Hallucination, auditory 1 (1.0) 0 1 (1.0) 1 (1.2) 0 1 (0.9)
Hallucination, tactile 1 (1.0) 0 1 (1.0) 0 0 0
Agitation 0 0 0 5 (5.8) 0 5 (4.6)
Insomnia 0 0 0 3 (3.5) 0 3 (2.8)
Abnormal behaviour 0 0 0 1 (1.2) 0 1 (0.9)
Aggression 0 0 0 1 (1.2) 0 1 (0.9)
Alcohol abuse 0 0 0 0 1 (4.5) 1 (0.9)
Delusion 0 0 0 0 1 (4.5) 1 (0.9)
Hallucination 0 0 0 1 (1.2) 0 1 (0.9)
Paranoia 0 0 0 1 (1.2) 0 1 (0.9)
Psychiatric decompensation 0 0 0 1 (1.2) 0 1 (0.9)
Schizophrenia, paranoid type 0 0 0 1 (1.2) 0 1 (0.9)
Tremor 0 0 0 2 (2.3) 0 2 (1.9)
Akathisia 0 0 0 1 (1.2) 0 1 (0.9)
Convulsion 0 0 0 1 (1.2) 0 1 (0.9)
Dystonia 0 0 0 0 1 (4.5) 1 (0.9)
Parkinsonism 0 0 0 0 1 (4.5) 1 (0.9)
Salivary hypersecretion 0 0 0 2 (2.3) 0 2 (1.9)
Gastrooesophageal reflux disease 0 0 0 1 (1.2) 0 1 (0.9)
Muscle rigidity 0 0 0 2 (2.3) 0 2 (1.9)
Bradycardia 0 0 0 1 (1.2) 0 1 (0.9)
Irritability 0 0 0 1 (1.2) 0 1 (0.9)
Hypochloraemia 0 0 0 1 (1.2) 0 1 (0.9)
Hyponatraemia 0 0 0 1 (1.2) 0 1 (0.9)
Pneumonia 0 0 0 0 1 (4.5) 1 (0.9)
Note: Group A consists of all patients who completed the study on 150 mg eq. and stayed on intensive PK sampling throughout; and Group B consists of all
patients who completed the study on 150 mg but were not on intensive PK sampling. Group C consists of patients who withdrew early while on 150 mg eq. and
intensive PK sampling. Group D consists of patients who completed the trial while on flexible dose and switched to non-intensive PK sampling (N = 9); patients
who withdrew from the trial while on 150 mg eq. and switched to non-intensive sampling (N = 3); and patients who withdrew from the trial while on flexible
dose and switched to non-intensive sampling (N = 10)
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[28], was reached within 2 to 4 days after the first dose.
This is within the range (60-80%) associated with anti-
psychotic efficacy [29-33]. This also confirms that the
150 mg eq. initiation dose administered in the deltoid
muscle (using a weight-adjusted needle length) resulted
in rapid attainment of target plasma paliperidone con-
centrations. Steady-state plasma concentrations of pali-
peridone were reached after approximately 8 to 9
months and the plasma concentrations were within the
predicted range by the population PK model. The med-
ian concentrations profile of paliperidone during the
first 3 months was consistent with those from a pre-
vious phase-3 study [23].
The study also allowed an opportunity to look at how
the PK results were impacted by ethnicity, given the
diversity of demographic characteristics of the study
population, with enrollment of a large number of Asian
participants. The population PK analyses of this data
revealed that, Asian patients had higher plasma expo-
sure to paliperidone than White patients; this could be
attributed to the lower BMI in Asians. However, across
studies, it has been found that BMI rather than ethni-
city, has the most impact on the PK of PP, but this is
overcome by the recommended dosing regimen and use
of appropriate needle length [34].
Metabolic adverse effects such as dose-related weight
gain (≤ 2.6 kg) have been reported in earlier studies
with PP [10,21-23]. Consistent with these earlier results,
average weight increased (approximately 2.5 kg) in the
course of the 1-year study. This weight gain was lower
than that observed with other atypical antipsychotics
such as olanzapine (4.15 kg over a 10-week treatment
period) [35]. Also consistent with previous data, there
were a low proportion of treatment-emergent glucose-
related adverse events in the current study, and no clini-
cally relevant changes in lipid profile were noted
[10,22-24]. Underlying risk factors were identified for
each of the patients with glucose-related adverse events,
suggesting that PP was not the primary cause.
Approximately one-fourth of the patients experienced
at least one EPS-related TEAE during this study. A
majority of the EPS-related TEAEs in this study were
nonserious. Most of these incidences occurred during
the first month of treatment and the rate subsequently
decreased to < 5% throughout. There were only 4
reported discontinuations due to EPS-related events.
The EPS scales indicated distinct increases in the rates
of parkinsonism (16%), while rates for akathisia and dys-
kinesia were low (1-2%). The proportion of patients
requiring anticholinergic medications at endpoint was
consistent to those reported earlier for PP [10,21-23].
Despite long-term treatment with the 150 mg eq. dose
in this study, only one case of mild TD was reported in
this study. The event resolved on continued PP
treatment, making the diagnosis of TD uncertain. This
low incidence of TD is consistent with results of a pre-
vious 33-week study with PP, where only one incidence
of TD was reported at 100 mg eq. dose [21]. There were
no reports of TD in the previous short-term PP schizo-
phrenia studies across dose ranges 25 to 150 mg eq.
[10,22-24].
As expected, increases in prolactin levels were greater
in women than in men, consistent with previous data
[10,22-24]. However, the incidence of prolactin-related
TEAEs was higher in this study than previous phase 3
PP studies, in which the incidence of potentially prolac-
tin-related TEAEs was low (ranging from ≤ 1-2%), con-
sistent with the generally lower doses used and the
shorter treatment period of those studies [10,21-24].
The increased prolactin levels in women gradually
declined at the end of the study. Importantly, most of
the potentially prolactin- related TEAEs observed in this
phase-1 study were reported as isolated laboratory
abnormalities, and patients were generally asymptomatic
with a few exceptions.
There are several limitations to this study. Firstly, this
study did not include a placebo group, such that no back-
ground rates of TEAE incidences were available for com-
parison. This limits the clinical interpretation of the data.
Also, this study was designed as a safety study and effi-
cacy measurements were secondary objectives. Because
the patients enrolled in this study were symptomatically
stable, the efficacy results cannot be extrapolated to
patients with acute schizophrenia. Though efficacy was
not the primary objective of the study, patients generally
remained stable both symptomatically and functionally
throughout the study. As the average age of patients was
between 25-50 years and no elderly patients were
included, these results cannot be generalized to either a
pediatric or geriatric population. Hyperprolactinemia is a
common adverse effect associated with antipsychotic
agents. For patients with elevated prolactin concentra-
tions, the practitioners are apt to query for presence of
clinical symptoms related to hyperprolactinemia. No spe-
cific queries for prolactin-related adverse events were
required as per the study protocol. Depending upon the
nature of such events and the doctor-patient relationship,
patients may or may not be forthcoming in reporting
them. Hence, it is possible that prolactin-related adverse
events have been underreported.
Conclusions
Long-term treatment with the highest available dose of
PP (150 mg eq.) was tolerable in patients with stable
schizophrenia and the pattern of the most common
adverse events was generally consistent with the known
safety profile for the compound. Injection site tolerabil-
ity was good. No new safety signals emerged.
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Paliperidone exposure approached steady-state from the
second injection (day 8) onwards, and steady-state levels
were reached after 8 to 9 months.
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